Human pluripotent stem cells can be genome modified and differentiated into almost any cell type of the human body, serving as a transformative model for human research and medicine. VGER has developed hPSC genome‑editing workflows that parallel our well-established processes in mice. Our expertise in CRISPR/Cas9 guide design and transfection has generated hPSCs with gene knockouts, point mutations, and larger insertions, including degron fusion proteins.
These genome editing workflows are applied to both human induced pluripotent stem cells (hiPSCs) and embryonic stem cells (hESCs) cultured on Matrigel in commercially produced mTeSR1 media. We perform PCR-based screening assays and advanced sequencing technologies to ensure accurate edits. All edited cell lines routinely undergo clonal isolation, freeze/thaw morphology assessment, and mycoplasma testing.
Genome edited human pluripotent stem cells with precise deletions and insertions up to 4 kb using CRISPR/HiFi Cas9 are generally produced within 3-6 months provided the desired mutation does not negatively impact hPSC growth, proliferation, or survival. Each project is different and delays can occur.
VGER maintains stocks of H9 hESCs (WiCell) and WTC-11 hiPSCs (Cornell) for use with MTA approval.
Created in https://BioRender.com